Abstract
Formation of new blood vessels is regulated by pro‐ and anti‐angiogenic factors, including VEGF and its secreted receptor sFlt1. With the goal of evaluating sFlt1 as a therapeutic for ocular diseases in dogs, we undertook the generation of recombinant canine sFlt1 (rcsFlt1) protein. Canine sFlt1 coding sequence was recovered as recombinant baculovirus after transfection into Sf9 cells. rcsFlt1 proteins were purified from infected Sf9 conditioned media by adsorption to heparin‐agarose and resolved by SDS‐PAGE. Immunoblotting of heparin‐purified conditioned medium revealed rcsFlt1 of predicted molecular weight (~115 kDa). rcsFlt1 migrated on SDS‐PAGE as a species apparently larger than recombinant mouse sFlt1 similarly produced. Endoglycosidase treatment of canine and mouse rsFlt1 reduced both to co‐migrating species of ~80 kDa, consistent with their predicted primary structures. This result, together with the presence of more predicted N‐glycosylation sites on canine than mouse sFlt1, suggests that differential glycosylation accounts for differential migration of canine and mouse forms. Future studies will examine the topical tolerability of purified rcsFlt1 on canine eyes. Supported by VMRCVM RGS
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
